跳至主要内容
临床试验/NCT01369719
NCT01369719已完成不适用

Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas

Hormozgan University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
138
试验地点
1
主要终点
Ferritin level

研究概览

简要总结

Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral iron chelators reduce iron overload in transfusion dependent patients. The aim of this study is to compare the efficacy and safety of osveral and desferal in transfusional iron overload patients with β-Thalassemia and intermediate Thalassemia in Bandarabbas.

详细描述

This is a double blinded randomized controlled trial on Efficacy and safety of Osveral and Desferal in thalassemic patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed intermedia or major thalassemia
  • More then 2 years old
  • Serum Ferritin level > 1000
  • Normal Creatinine and Complete Blood Count (CBC)

排除标准

  • HCV, HBV or HIV positive patients

研究组 & 干预措施

Osveral

Experimental

20 mg/kg oral osveral daily

干预措施: osveral (Drug)

desferal

Active Comparator

40mg/kg desferal for 6 nights in a week subcutaneously

干预措施: Desferal (Drug)

结局指标

主要结局

Ferritin level

时间窗: 8 months

ferritin level in months 4 and 8 of the study

次要结局

  • Hemoglobin level(8 month)
  • Drug side effects(8 months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Efficacy and Safety of Desferal Versus Osveral in... | 临床试验